Philip Glyn Jones

This inventor holds 16 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: Sunovion Pharmaceuticals Inc., Pgi Drug Discovery LLC, Sumitomo Pharma America, Inc.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philip Glyn Jones. Retrieved from https://idiyas.com/inventor/philip-glyn-jones

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 8)

% Patents Active = 81.3

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Danvers, MA (US) (2014 - 2021)
Marlborough, MA (US) (2021 - 2024)
Montgomery, TX (US) (2024)

Company Filing History:

14 out of 130

Sunovion Pharmaceuticals Inc.

patents

6 out of 16

Pgi Drug Discovery LLC

patents

1 out of 2

Sumitomo Pharma America, Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12053916 - Fishing lure injection molding using additive manufacturing (2024-08-06),

2. 11958862 - Compounds and compositions and uses thereof (2024-04-16),

3. 11192885 - 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders (2021-12-07),

4. 10927124 - Compounds and compositions and uses thereof (2021-02-23),

5. 10604536 - Substituted cyclopropanes as PDE-10 inhibitors (2020-03-31),

6. 10336732 - 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders (2019-07-02),

7. 10196403 - Compounds and compositions and uses thereof (2019-02-05),

8. 9994590 - Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors (2018-06-12),

9. 9951088 - D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders (2018-04-24),

10. 9856274 - Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors (2018-01-02),

11. 9856238 - 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders (2018-01-02),

12. 9834564 - Substituted quinolines as PDE-10 inhibitors (2017-12-05),

13. 9670230 - Heteroaryl compounds and methods of use thereof (2017-06-06),

14. 9249162 - Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors (2016-02-02),

15. 8969349 - Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors (2015-03-03),

Title: Inventor Philip Glyn Jones: Pioneering Innovations in Danvers

Introduction: Philip Glyn Jones is a distinguished inventor based in Danvers, Massachusetts, known for his groundbreaking contributions to various technological fields.

Latest Patents: Philip Glyn Jones holds several patents in the areas of renewable energy, artificial intelligence, and medical devices, showcasing his versatility and ingenuity in the realm of innovation.

Career Highlights: With a career spanning over two decades, Philip Glyn Jones has worked with renowned research institutions and leading companies to develop cutting-edge solutions that have had a significant impact on society.

Collaborations: Throughout his career, Philip Glyn Jones has collaborated with top engineers, scientists, and designers, fostering a culture of innovation and excellence in all his projects.

Conclusion: Philip Glyn Jones continues to push the boundaries of technology and inspire the next generation of inventors with his visionary ideas and relentless pursuit of innovation.

Profile summary based on public USPTO records.